Drug Profile
SYHA 1801
Alternative Names: SYHA-1801Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2023 SYHA 1801 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (CSPC Pharmaceutical Group pipeline, April 2023)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
- 07 Apr 2020 CSPC ZhongQi Pharmaceutical Technology initiates a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT04309968)